Results 301 to 310 of about 1,957,522 (351)

Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory. [PDF]

Adv Lab Med
Velilla TA, Prendes CF, Grau NA, Calmarza P, Anguila SC, Estébanez BC, Castro MJC, Ceacero D, Martínez IG, Palencia MM, Foncillas JP, Román CR, SEQCML Working Group on Lipoproteins and Cardiovascular Diseases.   +12 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Comment to: Factors affecting SARS-CoV-2 transmission among face mask users. [PDF]

Einstein (Sao Paulo)
Mattiuzzi C, Lippi G.
europepmc   +1 more source

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

Molecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger, Dorin Bar‐Ziv, Harriet Kluger   +2 more
wiley   +1 more source

Author Correction: Systematic protein-protein interaction mapping for clinically relevant human GPCRs. [PDF]

Mol Syst Biol
Sokolina K, Kittanakom S, Snider J, Kotlyar M, Maurice P, Gandía J, Benleulmi-Chaachoua A, Tadagaki K, Oishi A, Wong V, Malty RH, Deineko V, Aoki H, Amin S, Yao Z, Morató X, Otasek D, Kobayashi H, Menendez J, Auerbach D, Angers S, Pržulj N, Bouvier M, Babu M, Ciruela F, Jockers R, Jurisica I, Stagljar I.   +27 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Comparative Analyses Between Vulnerability Biomarkers of Aging and Health Biomarkers in Middle-Aged and Older Female Adults. [PDF]

Healthcare (Basel)
Knoblauch KKB, Losnack LF, Zacarias GC, Satyro GG, Villar R, Zago AS.   +5 more
europepmc   +1 more source

MIF as an oncogenic driver of low‐heterogeneity melanomas

Molecular Oncology, EarlyView.
Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Harriet M. Kluger, Richard Bucala   +4 more
wiley   +1 more source

Relation of skinfold thickness with the serum lipids, glucose and blood pressure among Indian sedentary office workers. [PDF]

J Health Popul Nutr
Naik NG, Chandrasekaran B, Patil RN, Kamath SU.   +3 more
europepmc   +1 more source

Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. <i>Cancers</i> 2020, <i>12</i>, 3412. [PDF]

Cancers (Basel)
Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT.   +13 more
europepmc   +1 more source